Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mapping the lipid droplet proteome by using proximity labeling in ccRCC cell lines

ABSTRACT: Comprehensive understanding of the lipid droplet (LD) proteome in ccRCC cells is lacking. In this study, we employed TurboID, an engineered biotin ligase with great efficiency for enzyme-catalyzed proximity labeling, to map the spatial proteome of LDs in ccRCC cells.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Disease Free

SUBMITTER: Hao Wang

LAB HEAD: Hao Wang

PROVIDER: PXD048174 | Pride | 2025-08-28

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	OFL002345-RCC4-HIL-1-1.raw	Raw
	OFL002345-RCC4-HIL-1-2.raw	Raw
	OFL002345-RCC4-HIL-bio-1-1.raw	Raw
	OFL002345-RCC4-HIL-bio-1-2.raw	Raw
	OFL002345-RCC4-HIL-bio-2-1.raw	Raw

Items per page:

1 - 5 of 16

Similar Datasets

Proteomics analysis of lipid droplets proteins in ccRCC cells

Project description:Deposition of lipid droplets (LDs) is a hallmark of clear cell renal cell carcinoma (ccRCC).LD functions are regulated by a complement of integral and peripheral proteins that associate with the bounding LD phospholipid monolayer. By employing proximity labeling with TurboID fusion constructs which targeting to LD, we mapped LD proteome in live ccRCC cell lines. These data provide an important resource for future LD studies in ccRCC and other tumors.

2025-08-28 | PXD053832 | Pride

Expression data from ccRCC specimens

Project description:To identify a therapeutic candidate target molecule for ccRCC, we analyzed the microRNA (miRNA) expression signatures in ccRCC clinical specimens. 9 matched pair (normal tissue and ccRCC tissue) plus 7 ccRCC tissue were analyzed for miRNA-microarray

2014-02-20 | E-GEOD-55138 | biostudies-arrayexpress

MicroID: A Novel Biotin Ligase Enables Rapid Proximity Ligation Proteomics

Project description:Identifying protein-protein interactions is central to dissecting signaling and regulatory processes in cells. BioID is a proximity ligation method that uses a promiscuous biotin ligase to detect protein-protein interactions in cells in a highly reproducible manner. Recent advancements in proximity ligation tools have improved efficiency and timing of labeling, allowing for measurement of interactions on a cellular timescale. However, issues of size, stability, and background labeling of these constructs persist. Here we modified the structure of BioID2 to create a smaller, highly active, biotin ligase that we named MicroID. Truncation of the c-terminal of BioID2 and mutations to alleviate blockage of biotin/ATP binding at the active site of BioID2 resulted in a smaller, highly active construct with lower baseline labeling. Several additional point mutations improved the function of our modified MicroID construct compared to BioID2 and other biotin ligases, including TurboID and miniTurbo. MicroID is the smallest biotin ligase (180 AA for microID vs. 257 AA for miniTurbo and 338 AA for TurboID), yet it demonstrates only slightly less labeling activity than TurboID and outperforms miniTurboID. MicroID also had lower background labeling than TurboID. For experiments where precise temporal control of labeling is essential, we developed a MicroID mutant that has lower labeling efficiency, but significantly reduced biotin scavenging compared to BioID2. Finally, we demonstrate utility of MicroID in mass spectrometry experiments by localizing MicroID constructs to subcellular organelles and measuring protein-protein interactions.

2022-08-12 | PXD031146 | Pride

Expression data from ccRCC specimens

Project description:To identify a therapeutic candidate target molecule for ccRCC, we analyzed the microRNA (miRNA) expression signatures in ccRCC clinical specimens.

2014-02-20 | GSE55138 | GEO

Proteomics analysis on SETD2 loss induced ccRCC formation

Project description:Patients with polycystic kidney disease (PKD) encounter a high risk of clear cell renal cell carcinoma (ccRCC), a malignant tumor with dysregulated lipid metabolism. SET domain–containing 2 (SETD2) has been identified as an important tumor suppressor gene in ccRCC. However, the role of SETD2 in tumorigenesis during the transition from PKD to ccRCC remains largely unexplored. Herein, we performed metabolomics, lipidomics, transcriptomics and proteomics with SETD2 loss induced PKD-ccRCC transition mouse model. To characterize biological responses triggered by SETD2 deletion during PKD-ccRCC transition at the protein level, we conducted global proteomics studies.

2023-10-31 | PXD038966 | Pride

miRNA sequencing in ccRCC

Project description:miRNA sequencing in ccRCC

| PRJNA431817 | ENA

Analysis of ccRCC derived cell lines

Project description:This SuperSeries is composed of the following subset Series: GSE34979: Array-based CGH analysis of ccRCC derived cell lines GSE34981: miRNA transcript levels in ccRCC-derived cell lines and proximal tubular epithelial cell samples Refer to individual Series

2012-11-01 | E-GEOD-34985 | biostudies-arrayexpress

BMAL1-HIF2α heterodimers contribute to ccRCC

Project description:Circadian disruption enhances cancer risk, and many tumors exhibit disordered circadian gene expression. We show rhythmic gene expression is unexpectedly robust in clear cell renal cell carcinoma (ccRCC). Furthermore, the clock gene BMAL1 is higher in ccRCC than in healthy kidneys, unlike in other tumor types. BMAL1 is closely related to ARNT and we show that BMAL1-HIF2α regulates a subset of HIF2α target genes in ccRCC cells. Depletion of BMAL1 reprograms HIF2α chromatin association and target gene expression and reduces ccRCC growth in culture and in xenografts. Analysis of pre-existing data reveals higher BMAL1 in patient-derived xenografts that are sensitive to growth suppression by HIF2α antagonists. We show that increasing BMAL1 sensitizes ccRCC-derived A498 cells to growth inhibition by PT2399. Together, these findings indicate that an alternate HIF2α heterodimer containing the circadian partner BMAL1 contributes to HIF2α activity, growth, and sensitivity to HIF2α antagonist drugs in ccRCC cells.

2025-03-17 | GSE290669 | GEO

cis-regulatory landscape in ccRCC [tissue]

Project description:VHL loss is the most common genetic alteration event in ccRCC, but its effect on epigenetic landscape has not been elucidated previously. By performing histone modifications (H3K27ac, H3K4me1, H3K4me3) from ccRCC cell lines, we describe the genome-wide cis-regulatory landscapes of VHL-deficient ccRCC tumors. We show that ccRCCs exhibit a pervasive gain of enhancers around hypoxic and metabolic transcriptional targets.

2017-08-22 | GSE86091 | GEO

cis-regulatory landscape in ccRCC [cell lines]

2017-08-22 | GSE86087 | GEO